Hyperfine

Hyperfine, Inc. is a medical device development company engaged in the development of, MRI solutions and non-invasive neural monitoring technology. The company was founded by Jonathan M. Rothberg on February 25, 2014 and is headquartered in Guilford, CT.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hyperfine reports Q4 revenue of $1.4M, eyes $14M revenue in 2023

Hyperfine's Q4 2022 earnings call highlighted financial performance, strategic achievements in 2022, challenges in net losses and expenses, and opportunities for revenue growth and expansion in 2023. The company's focus on innovation, partnerships, and commercial progress underpins its outlook for the coming year.

Hyperfine reports record revenue in Q1 2023, eyes U.S. expansion

Hyperfine's Q1 2023 performance reflects strong revenue growth and strategic advancements in FDA clearances and partnerships. While facing significant expenses and cash burn, the company maintains a positive outlook for revenue and growth opportunities through innovation and market expansion.

Hyperfine reports record revenue in Q2 2023 amidst strategic expansion

Hyperfine's Q2 2023 earnings call reflects strong revenue growth, strategic focus on critical care and pediatric markets, and ongoing investment in technology and clinical studies. Despite financial challenges, the company maintains a positive outlook with a clear roadmap for future growth. Managing expenses and cash burn while pursuing innovation will be key to sustainable success.

Hyperfine reports robust Q3 earnings, eyes market expansion opportunities

Hyperfine's Q3 performance showcased strong revenue growth and improved financial metrics.
The company's focus on innovation and collaborations presents opportunities for market expansion.
Challenges include balancing investments in clinical studies while maintaining financial stability.

Hyperfine reports strong revenue growth and innovation focus for 2024

Hyperfine's Q4 2023 performance reflects robust revenue growth, strategic expansion into prestigious institutions, and a focus on cutting-edge healthcare solutions.
While facing financial challenges and a net loss, the company's commitment to innovation, FDA clearances, and market opportunities position it for future success.
With a strong 2024 revenue guidance, Hyperfine is poised to leverage its achievements in 2023, customer success, and international expansion to drive growth and profitability.

Hyperfine reports strong Q1 revenue growth and advances in medical imaging

Hyperfine's Q1 2024 performance reflects revenue growth driven by international contributions and advancements in clinical programs and commercial expansion.
While facing financial challenges and cash burn, the company maintains a positive outlook with plans for future growth and innovation in medical imaging technology.
Strategic strengths in AI software development and clinical applications position Hyperfine well to capture opportunities in the healthcare market and drive revenue growth.

Hyperfine reports robust Q3 growth, eyes international expansion opportunities

Hyperfine's Q3 2024 performance reflects strong revenue growth and operational efficiency improvements.
The company's focus on innovation, clinical efficacy, and market expansion presents opportunities for sustained growth.
However, managing cash burn, meeting revenue targets, and navigating competitive pressures remain key challenges for Hyperfine.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hyperfine, Inc. is a medical device development company, which engages in providing imaging and monitoring through magnetic resonance imaging to revolutionize healthcare for people. It also develops imaging of health conditions through its Swoop portable magnetic resonance. The company was founded by Jonathan M. Rothberg and Ronald Walsworth on February 25, 2014 and is headquartered in Guilford, CT.

Hyperfine, Inc. (NASDAQ:HYPR ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Maria Sainz - President, Chief Executive Officer Brett Hale - Chief Administrative Officer, Incoming Chief Financial Officer Marissa Bych - Investor Relations, The Gilmartin Group Conference Call Participants Larry Biegelsen - Wells Fargo Kevin Joaquin - Evercore ISI Neil Chatterji - B. Riley Operator Thank you for standing by and welcome to Hyperfine's Fourth Quarter and Full Year 2022 Conference Call.

Hyperfine, Inc. (HYPR) Q4 2022 Earnings Call Transcript

GUILFORD, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system™ today announced fourth quarter and full year 2022 financial results and provided a business update.

Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

GUILFORD, Conn., March 06, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system, today announced that it will report financial results for the fourth quarter and full year 2022 on Tuesday, March 21, 2023. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results on March 21, 2023

Swoop® Portable MR Imaging® system positioned to offer even greater clinical utility in neurocritical care Swoop® Portable MR Imaging® system positioned to offer even greater clinical utility in neurocritical care

Hyperfine, Inc. Receives FDA Clearance for Updated Software to Further Improve Diffusion-Weighted Imaging

Penny stocks to watch this week. The post Hot Penny Stocks Under $5 To Watch Before March 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks Under $5 To Watch Before March 2023

CE Marking for the company's portable MRI system with AI-powered imaging software demonstrates that the system complies with safety and performance requirements in the EU and provides the company optionality for future expansion beyond the current commercial focus CE Marking for the company's portable MRI system with AI-powered imaging software demonstrates that the system complies with safety and performance requirements in the EU and provides the company optionality for future expansion beyond the current commercial focus

Hyperfine, Inc. Swoop® Portable MR Imaging® System Receives CE Marking After Meeting Comprehensive New EU MDR Regulations

Latest Swoop® software improves image quality for DWI imaging of the brain Latest Swoop® software improves image quality for DWI imaging of the brain

Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop® Portable MR Imaging® System

New study utilizes Hyperfine, Inc. portable MRI system in monitoring brain injury and evaluating physiological impacts New study utilizes Hyperfine, Inc. portable MRI system in monitoring brain injury and evaluating physiological impacts

Latest Data Demonstrate Potential of the Swoop® Portable MR Imaging® System in the Follow-up of Stroke Patients Who Have Received a Thrombectomy

GUILFORD, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that Brett Hale will join Hyperfine, Inc. on February 13, 2023 and will serve as Chief Administrative Officer & Chief Financial Officer (CFO). Alok Gupta, who currently serves as CFO, will step down on or about March 31 after a transition period.

Hyperfine, Inc. Announces Brett Hale as New Chief Administrative Officer & Chief Financial Officer

Research highlights the significance and clinical relevance of portable MRI technology Research highlights the significance and clinical relevance of portable MRI technology

Hyperfine Swoop® Point-of-Care MRI System™ Takes the Stage at ISMRM with Twelve Abstract Inclusions

GUILFORD, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that the company will be participating in the upcoming 5th Annual Evercore ISI HealthCONx Conference.

Hyperfine to Present at the 5th Annual Evercore ISI HealthCONx Conference

Hyperfine, Inc. (NASDAQ:HYPR ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Marissa Bych – Investor Relations Maria Sainz – President and Chief Executive Officer Alok Gupta – Chief Financial Officer Scott Huennekens – Executive Chairman Conference Call Participants Larry Biegelsen – Wells Fargo Neil Chatterji – B. Riley Larry Biegelsen – Wells Fargo Operator Good afternoon, and welcome to Hyperfine's Third Quarter 2022 Earnings Conference Call.

Hyperfine, Inc. (HYPR) Q3 2022 Earnings Call Transcript

GUILFORD, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the third quarter 2022 on Thursday, November 10, 2022. Company management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine to Announce Third Quarter 2022 Financial Results on November 10, 2022

GUILFORD, Conn., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), (“Hyperfine” or “the Company”), the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it has named medical device industry veteran Maria Sainz as President and Chief Executive Officer (CEO) of Hyperfine, effective October 24, 2022. Scott Huennekens, who currently serves as interim President and CEO, will stay on as Executive Chairperson of the Board.

Hyperfine Names Maria Sainz President and Chief Executive Officer

Management to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase and the 2022 Wells Fargo Healthcare Conference in Boston Management to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase and the 2022 Wells Fargo Healthcare Conference in Boston

Hyperfine to Participate in Upcoming Investor Conferences

Hyperfine, Inc. (NASDAQ:HYPR ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group LLC Scott Huennekens - Interim President and Chief Executive Officer Alok Gupta - Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Operator Ladies and gentlemen, thank you for standing by and welcome to the Hyperfine Q2 2022 Earnings Conference Call. At this time all participants are in a listen-only mode.

Hyperfine, Inc. (HYPR) CEO Scott Huennekens on Q2 2022 Results - Earnings Call Transcript

GUILFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today reported financial results for the quarter ended June 30, 2022. Management will host a corresponding conference call today at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine Reports Second Quarter 2022 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Viz.ai and Hyperfine, Inc. will partner to bring MRI to the bedside and deliver key insights to the clinician's fingertips for quick decision making.

Viz.ai Partners with Hyperfine to Enable New MR Imaging and Workflow Paradigm

GUILFORD, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the second quarter 2022 on Wednesday, August 10, 2022. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Hyperfine to Announce Second Quarter 2022 Financial Results on August 10, 2022

Groundbreaking Medical Device Company Unveils AI-Powered Software that Improves Diagnostic Imaging Experience for Young Patients Groundbreaking Medical Device Company Unveils AI-Powered Software that Improves Diagnostic Imaging Experience for Young Patients

Hyperfine Announces Zero Radiation Dose Rapid MR Imaging Test for Pediatric Hydrocephalus Patients

Launches global search for long-term CEO with Scott Huennekens to serve as interim President & CEO Reaffirms 2022 Financial Guidance

Hyperfine Announces CEO Transition

Alfred Health to receive first in nation portable MRI systems for point-of-care brain scans Alfred Health to receive first in nation portable MRI systems for point-of-care brain scans

Hyperfine Announces Expansion into Australia and New Zealand with Medical Device Registration and Notification

GUILFORD, Conn., May 25, 2022 (GLOBE NEWSWIRE) -- Hyperfine (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that management will be presenting at the upcoming 2022 Jefferies Global Healthcare Conference in New York, New York.

Hyperfine to Present at the 2022 Jefferies Global Healthcare Conference

Hyperfine, Inc. (NASDAQ:HYPR ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group IR Dave Scott - President and CEO Alok Gupta - CFO Conference Call Participants Lawrence Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Operator Good afternoon, and welcome to Hyperfine's First Quarter 2022 Earnings Conference Call. At this time all participants are in listen-only mode.

Hyperfine, Inc. (HYPR) CEO Dave Scott on Q1 2022 Results - Earnings Call Transcript

GUILFORD, Conn., May 11, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today reported financial results for the quarter ended March 31, 2022. Management will host a corresponding conference call to discuss the financial results and provide a business update today at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

News for Hyperfine Stock (HYPR)